中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1437-1442

Risk factors and mechanisms of liver injury in patients with acquired immunodeficiency syndrome

DOI: 10.12449/JCH250732

  • Shandong Public Health Clinical Center Affiliated to Shandong University，Jinan 250100，China

Research funding:

Key R & D Plan of Shandong Province (2021SFGC0504)

More Information
  • Corresponding author: LI Qiang， doctorliqiang@aliyun.com （ORCID： 0000-0002-8667-4676）
  • Received Date: 2024-10-07
  • Accepted Date: 2024-12-27
  • Published Date: 2025-07-25
    Abstract
  • With the advent of the era of antiretroviral therapy， the lifespan of individuals living with human immunodeficiency virus （HIV） infection has been extended significantly， and there is a significant increase in the incidence rate of non-acquired immunodeficiency syndrome （AIDS）-related diseases， among which liver disease is one of the main causes of non-AIDS-related deaths. There is still a relatively high incidence rate of liver injury in patients with HIV infection， and there are various causes of liver injury. This article reviews the possible risk factors for liver injury and related mechanisms from the aspects of HIV infection， co-infection with hepatitis B virus/hepatitis C virus and other pathogens， drugs， metabolic dysfunction， and intestinal bacterial translocation， in order to provide a reference for the management of individuals with HIV infection.

     

    • FullText(HTML)
  • loading
    • References(59)
  • [1]
    ZHAO Y, WEI L, DOU ZH, et al. Changing mortality and patterns of death causes in HIV infected patients-China, 2013-2022[J]. China CDC Wkly, 2023, 5( 48): 1073- 1078. DOI: 10.46234/ccdcw2023.201.
    [2]
    AZOULAY É, de CASTRO N, BARBIER F. Critically ill patients with HIV: 40 years later[J]. Chest, 2020, 157( 2): 293- 309. DOI: 10.1016/j.chest.2019.08.002.
    [3]
    BAKASIS AD, ANDROUTSAKOS T. Liver fibrosis during antiretroviral treatment in HIV-infected individuals. truth or tale?[J]. Cells, 2021, 10( 5): 1212. DOI: 10.3390/cells10051212.
    [4]
    KASPAR MB, STERLING RK. Mechanisms of liver disease in patients infected with HIV[J]. BMJ Open Gastroenterol, 2017, 4( 1): e000166. DOI: 10.1136/bmjgast-2017-000166.
    [5]
    TRICKEY A, MCGINNIS K, GILL MJ, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: A collaboration of cohort studies[J]. Lancet HIV, 2024, 11( 3): e176- e185. DOI: 10.1016/S2352-3018(23)00272-2.
    [6]
    WEBER MR, DURAN RAMIREZ JJ, HENTZIEN M, et al. Time trends in causes of death in people with HIV: Insights from the Swiss HIV cohort study[J]. Clin Infect Dis, 2024, 79( 1): 177- 188. DOI: 10.1093/cid/ciae014.
    [7]
    LI FY, FENG Y, LIU X, et al. HBV and HCV co-infection in Chinese newly diagnosed HIV+subjects in 2015 and 2023: A cross-sectional study[J]. Pathogens, 2024, 13( 5): 367. DOI: 10.3390/pathogens13050367.
    [8]
    GUNTER HM, TATZ G, MAARTENS G, et al. Liver injury in people with HIV on antituberculosis and/or antiretroviral therapy-assessing causality using the updated roussel uclaf causality assessment method[J]. Pharmacoepidemiol Drug Saf, 2024, 33( 10): e5883. DOI: 10.1002/pds.5883.
    [9]
    BIAŁY M, CZARNECKI M, INGLOT M. Impact of combination antiretroviral treatment on liver metabolic health in HIV-infected persons[J]. Viruses, 2023, 15( 12): 2432. DOI: 10.3390/v15122432.
    [10]
    SHAMANNA SB, NAIK RRR, HAMIDE A. Causes of liver disease and its outcome in HIV-infected individuals[J]. Indian J Gastroenterol, 2016, 35( 4): 310- 314. DOI: 10.1007/s12664-016-0676-6.
    [11]
    WEBER R, SABIN CA, FRIIS-MØLLER N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study[J]. Arch Intern Med, 2006, 166( 15): 1632- 1641. DOI: 10.1001/archinte.166.15.1632.
    [12]
    CAINELLI F, VENTO S. Liver disease in patients with HIV in sub-Saharan Africa[J]. Lancet HIV, 2015, 2( 10): e412- e413. DOI: 10.1016/S2352-3018(15)00179-4.
    [13]
    LIU S, ZHOU Y, WANG Y, et al. The correlated risk factors for severe liver damage among HIV-positive inpatients with abnormal liver tests[J]. Front Med(Lausanne), 2022, 9: 817370. DOI: 10.3389/fmed.2022.817370.
    [14]
    WEN LJ, SI G, LONG B, et al. Analysis of liver injury and its influencing factors in HIV/AIDS patients in Mianyang Area[J]. J Med Pest Control, 2024, 40( 11): 1066- 1069. DOI: 10.7629/yxdwfz202411006.

    文丽娟, 司果, 龙波, 等. 绵阳地区HIV/AIDS患者肝损伤及影响因素分析[J]. 医学动物防制, 2024, 40( 11): 1066- 1069. DOI: 10.7629/yxdwfz202411006.
    [15]
    ROCKSTROH JK, MOHR R, BEHRENS G, et al. Liver fibrosis in HIV: Which role does HIV itself, long-term drug toxicities and metabolic changes play?[J]. Curr Opin HIV AIDS, 2014, 9( 4): 365- 370. DOI: 10.1097/COH.0000000000000064.
    [16]
    DEBES JD, BOHJANEN PR, BOONSTRA A. Mechanisms of accelerated liver fibrosis progression during HIV infection[J]. J Clin Transl Hepatol, 2016, 4( 4): 328- 335. DOI: 10.14218/JCTH.2016.00034.
    [17]
    LEUMI S, BIGNA JJ, AMOUGOU MA, et al. Global burden of hepatitis B infection in people living with human immunodeficiency virus: A systematic review and meta-analysis[J]. Clin Infect Dis, 2020, 71( 11): 2799- 2806. DOI: 10.1093/cid/ciz1170.
    [18]
    PLATT L, EASTERBROOK P, GOWER E, et al. Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis[J]. Lancet Infect Dis, 2016, 16( 7): 797- 808. DOI: 10.1016/S1473-3099(15)00485-5.
    [19]
    CRANE M, AVIHINGSANON A, RAJASURIAR R, et al. Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus(HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy[J]. J Infect Dis, 2014, 210( 5): 745- 751. DOI: 10.1093/infdis/jiu119.
    [20]
    XU M, WARNER C, DUAN XQ, et al. HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α-and TGF-β1-dependent pathway[J]. J Hepatol, 2024, 80( 6): 868- 881. DOI: 10.1016/j.jhep.2024.01.026.
    [21]
    SINGH KP, AVIHINGSANON A, ZERBATO JM, et al. Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy[J]. EBioMedicine, 2024, 102: 105054. DOI: 10.1016/j.ebiom.2024.105054.
    [22]
    LIN WY, WEINBERG EM, CHUNG RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection[J]. J Infect Dis, 2013, 207( Suppl 1): S13- S18. DOI: 10.1093/infdis/jis926.
    [23]
    JANG JY, SHAO RX, LIN WY, et al. HIV infection increases HCV-induced hepatocyte apoptosis[J]. J Hepatol, 2011, 54( 4): 612- 620. DOI: 10.1016/j.jhep.2010.07.042.
    [24]
    CEVALLOS C, JARMOLUK P, SVIERCZ F, et al. Bystander effects and profibrotic interactions in hepatic stellate cells during HIV and HCV coinfection[J]. J Immunol Res, 2024, 2024: 6343757. DOI: 10.1155/2024/6343757.
    [25]
    MEULEMAN P, LIBBRECHT L, WIELAND S, et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus[J]. J Virol, 2006, 80( 6): 2797- 2807. DOI: 10.1128/JVI.80.6.2797-2807.2006.
    [26]
    YOON EJ, HU KQ. Hepatitis C virus(HCV) infection and hepatic steatosis[J]. Int J Med Sci, 2006: 53- 56. DOI: 10.7150/ijms.3.53.
    [27]
    CROWELL TA, GEBO KA, BALAGOPAL A, et al. Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV[J]. J Acquir Immune Defic Syndr, 2014, 65( 4): 429- 437. DOI: 10.1097/QAI.0000000000000059.
    [28]
    KONOPNICKI D, MOCROFT A, de WIT S, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort[J]. AIDS, 2005, 19( 6): 593- 601. DOI: 10.1097/01.aids.0000163936.99401.fe.
    [29]
    SU S, FAIRLEY CK, SASADEUSZ J, et al. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome[J]. J Med Virol, 2018, 90( 3): 518- 525. DOI: 10.1002/jmv.24988.
    [30]
    RAMÍREZ-MENA A, GLASS TR, WINTER A, et al. Prevalence and outcomes of hepatitis B coinfection and associated liver disease among antiretroviral therapy-naive individuals in a rural Tanzanian human immunodeficiency virus cohort[J]. Open Forum Infect Dis, 2016, 3( 3): ofw162. DOI: 10.1093/ofid/ofw162.
    [31]
    HUA L, ANDERSEN JW, DAAR ES, et al. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment[J]. AIDS, 2013, 27( 17): 2725- 2734. DOI: 10.1097/01.aids.0000432470.46379.dd.
    [32]
    WANG JY, HSUEH PR, WANG SK, et al. Disseminated tuberculosis: A 10-year experience in a medical center[J]. Medicine(Baltimore), 2007, 86( 1): 39- 46. DOI: 10.1097/MD.0b013e318030b605.
    [33]
    BUNCHORNTAVAKUL C, REDDY KR. Epstein-Barr virus and cytomegalovirus infections of the liver[J]. Gastroenterol Clin North Am, 2020, 49( 2): 331- 346. DOI: 10.1016/j.gtc.2020.01.008.
    [34]
    FERRARI DFL, SILVA JDM, BARBOSA AN, et al. Epidemiological and liver biomarkers profile of Epstein-Barr virus infection and its coinfection with cytomegalovirus in patients with hematological diseases[J]. Biomolecules, 2021, 11( 8): 1151. DOI: 10.3390/biom11081151.
    [35]
    BATHOBAKAE L, BASHIR R, WILKINSON T, et al. Non-hepatotropic viral hepatitis: A narrative review[J]. Scand J Gastroenterol, 2024, 59( 12): 1322- 1329. DOI: 10.1080/00365521.2024.2422947.
    [36]
    HUNTER PR, NICHOLS G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients[J]. Clin Microbiol Rev, 2002, 15( 1): 145- 154. DOI: 10.1128/CMR.15.1.145-154.2002.
    [37]
    O’HARA SP, SMALL AJ, GAJDOS GB, et al. HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum[J]. J Infect Dis, 2009, 199( 8): 1195- 1204. DOI: 10.1086/597387.
    [38]
    NASEER M, DAILEY FE, JUBOORI AA, et al. Epidemiology, determinants, and management of AIDS cholangiopathy: A review[J]. World J Gastroenterol, 2018, 24( 7): 767- 774. DOI: 10.3748/wjg.v24.i7.767.
    [39]
    PILLAYE JN, MARAKALALA MJ, KHUMALO N, et al. Mechanistic insights into antiretroviral drug-induced liver injury[J]. Pharmacol Res Perspect, 2020, 8( 4): e00598. DOI: 10.1002/prp2.598.
    [40]
    BRÜCK S, WITTE S, BRUST J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine[J]. Eur J Med Res, 2008, 13( 7): 343- 348.
    [41]
    TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800.
    [42]
    ZHANG CD, WANG W, ZHOU MY, et al. The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: A change in national treatment guidelines may be warranted[J]. J Acquir Immune Defic Syndr, 2013, 62( 5): 540- 545. DOI: 10.1097/QAI.0b013e3182845cc7.
    [43]
    CAO W, HSIEH E, LI TS. Optimizing treatment for adults with HIV/AIDS in China: Successes over two decades and remaining challenges[J]. Curr HIV/AIDS Rep, 2020, 17( 1): 26- 34. DOI: 10.1007/s11904-019-00478-x.
    [44]
    PETER J, CHOSHI P, LEHLOENYA RJ. Drug hypersensitivity in HIV infection[J]. Curr Opin Allergy Clin Immunol, 2019, 19( 4): 272- 282. DOI: 10.1097/ACI.0000000000000545.
    [45]
    PINTI M, SALOMONI P, COSSARIZZA A. Anti-HIV drugs and the mitochondria[J]. Biochim Biophys Acta, 2006, 1757( 5/6): 700- 707. DOI: 10.1016/j.bbabio.2006.05.001.
    [46]
    VISPO E, MORELLO J, RODRIGUEZ-NOVOA S, et al. Noncirrhotic portal hypertension in HIV infection[J]. Curr Opin Infect Dis, 2011, 24( 1): 12- 18. DOI: 10.1097/QCO.0b013e3283420f08.
    [47]
    GATHE JC Jr, PIERONE G, PILIERO P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients[J]. AIDS Res Hum Retroviruses, 2007, 23( 2): 216- 223. DOI: 10.1089/aid.2006.0178.
    [48]
    BREEN RM, MILLER RF, GORSUCH T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection[J]. Thorax, 2006, 61( 9): 791- 794. DOI: 10.1136/thx.2006.058867.
    [49]
    PUKENYTE E, LESCURE FX, REY D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment[J]. Int J Tuberc Lung Dis, 2007, 11( 1): 78- 84.
    [50]
    BRESSAN S, PIERANTONI A, SHARIFI S, et al. Chemotherapy-induced hepatotoxicity in HIV patients[J]. Cells, 2021, 10( 11): 2871. DOI: 10.3390/cells10112871.
    [51]
    WEGERMANN K, MOYLAN C, NAGGIE S. Fatty liver disease: Enter the metabolic era[J]. Curr HIV/AIDS Rep, 2023, 20( 6): 405- 418. DOI: 10.1007/s11904-023-00669-7.
    [52]
    PAIK JM, HENRY L, GOLABI P, et al. Presumed nonalcoholic fatty liver disease among medicare beneficiaries with HIV, 2006-2016[J]. Open Forum Infect Dis, 2020, 7( 1): ofz509. DOI: 10.1093/ofid/ofz509.
    [53]
    IVANOV AV, VALUEV-ELLISTON VT, IVANOVA ON, et al. Oxidative stress during HIV infection: Mechanisms and consequences[J]. Oxid Med Cell Longev, 2016, 2016: 8910396. DOI: 10.1155/2016/8910396.
    [54]
    KAZANKOV K, BARRERA F, MØLLER HJ, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease[J]. Liver Int, 2016, 36( 10): 1549- 1557. DOI: 10.1111/liv.13150.
    [55]
    SETH A, SHERMAN KE. Fatty liver disease in persons with HIV infection[J]. Top Antivir Med, 2019, 27( 2): 75- 82.
    [56]
    CHEW KW, WU KL, TASSIOPOULOS K, et al. Liver inflammation is common and linked to metabolic derangements in persons with treated human immunodeficiency virus(HIV)[J]. Clin Infect Dis, 2023, 76( 3): e571- e579. DOI: 10.1093/cid/ciac708.
    [57]
    NGANOU-MAKAMDOP K, DOUEK DC. The gut and the translocated microbiomes in HIV infection: Current concepts and future avenues[J]. Pathog Immun, 2024, 9( 1): 168- 194. DOI: 10.20411/pai.v9i1.693.
    [58]
    SANTINELLI L, ROSSI G, GIOACCHINI G, et al. The crosstalk between gut barrier impairment, mitochondrial dysfunction, and microbiota alterations in people living with HIV[J]. J Med Virol, 2023, 95( 1): e28402. DOI: 10.1002/jmv.28402.
    [59]
    PENG SX, LI CY, HUANG AP, et al. Human immunodeficiency virus infection comorbid with autoimmune hepatitis-primary biliary cholangitis overlap syndrome: A case report[J]. J Clin Hepatol, 2023, 39( 9): 2175- 2178. DOI: 10.3969/j.issn.1001-5256.2023.09.021.

    彭世秀, 李春燕, 黄爱萍, 等. HIV 感染合并自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征1例报告[J]. 临床肝胆病杂志, 2023, 39( 9): 2175- 2178. DOI: 10.3969/j.issn.1001-5256.2023.09.021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (361) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return